Today's edition · Sunday, November 22, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechWashington

Health & TechSeattle, Washington

A malaria vaccine blocked infection in 87% of volunteers in an early trial

In an NIH-sponsored phase 1 challenge trial led by UW Medicine, 13 of 15 people given PfSPZ-LARC2 stayed infection-free against a different malaria strain, versus none of 7 on placebo. Larger trials are still ahead.

Verified · Source: UW Medicine NewsroomNov 19, 2026 · 1 min read
How to help
A close view of an Anopheles mosquito
Illustrative photo of an Anopheles mosquito, which can carry malaria. This is not the trial, and no volunteers are shown. Jim Gathany / Wikimedia Commons · Public domain

Read the original

The reporting lives at UW Medicine Newsroom. Our summary is checked against it, and we link it on every story.

An experimental malaria vaccine blocked infection in 87 percent of volunteers in an early human trial led by UW Medicine, the university's newsroom reported. The NIH-sponsored phase 1 study used a human challenge. Of 15 people given PfSPZ-LARC2, 13 stayed infection-free when exposed 12 to 16 weeks later to a malaria strain different from the one in the vaccine. None of the 7 people on placebo stayed infection-free. The results were presented at the American Society of Tropical Medicine and Hygiene meeting.

This is an early-stage trial, not a finished vaccine campaign. Larger trials are still needed. The 13 of 15 and 0 of 7 figures are the challenge results in this small group.

More good news

Other stories in the same neighborhood of kindness.